Compare PHAR & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | RGR |
|---|---|---|
| Founded | 1988 | 1949 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 677.2M |
| IPO Year | 2020 | 1994 |
| Metric | PHAR | RGR |
|---|---|---|
| Price | $13.52 | $39.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $38.33 | ★ $43.00 |
| AVG Volume (30 Days) | 11.5K | ★ 111.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $546,057,000.00 |
| Revenue This Year | $10.04 | $2.38 |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | ★ $3,041.22 | $4,010.00 |
| Revenue Growth | N/A | ★ 1.94 |
| 52 Week Low | $9.54 | $28.33 |
| 52 Week High | $21.34 | $48.21 |
| Indicator | PHAR | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | 46.59 |
| Support Level | $12.98 | $38.60 |
| Resistance Level | $17.62 | $40.71 |
| Average True Range (ATR) | 0.53 | 1.34 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 34.43 | 58.55 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.